Phio Pharmaceuticals adds dermatology expert to board
I'm LongbridgeAI, I can summarize articles.Phio Pharmaceuticals announced the appointment of dermatologist R. Todd Plott, M.D., to its Board of Directors effective July 20, 2026. Plott brings three decades of dermatologic research and FDA advisory experience, aiming to strengthen the company's clinical and regulatory expertise for its lead candidate PH-762. The board size increased to six members. Analyst ratings remain mixed, with a Buy rating at $14.00 target, while TipRanks' AI suggests a Neutral stance due to weak financials despite positive clinical milestones.
An announcement from Phio Pharmaceuticals ( (PHIO) ) is now available.
Effective July 20, 2026, Phio Pharmaceuticals increased its Board of Directors to six members and appointed dermatologist and clinical researcher R. Todd Plott, M.D. as a director and Governance Committee member through the 2026 annual meeting. Plott will receive standard non-employee director compensation and enter into the company’s customary indemnification agreement, with Phio noting there are no related-party arrangements or transactions tied to his appointment.
In a press release issued July 21, 2026, the company highlighted Plott’s three decades of dermatologic research, clinical trial oversight and prior FDA advisory committee experience, which management views as directly supporting development of its lead INTASYL candidate PH-762 for squamous cell carcinoma and other skin cancers. The appointment is expected to strengthen Phio’s clinical and regulatory expertise as it advances RNAi-based oncology programs, providing additional governance and domain knowledge for stakeholders.
The most recent analyst rating on (PHIO) stock is a Buy
with a $14.00 price target.
To see the full list of analyst forecasts on Phio Pharmaceuticals stock,
see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue losses and sustained cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive recent clinical and manufacturing milestones provide an offset, but valuation support is limited given ongoing losses and no dividend.
To see Spark’s full report on PHIO stock,
click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on cancer therapeutics, developing treatments based on its proprietary INTASYL siRNA gene silencing technology. Its lead program, PH-762, targets the PD-1 gene as a potential non-surgical treatment for skin cancers, including cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
The company’s INTASYL compounds are designed to boost the activity of immune cells against tumors, positioning Phio in the RNAi-based oncology space with an emphasis on dermatologic malignancies. Phio is listed on Nasdaq under the ticker PHIO and is progressing its pipeline through early-stage clinical trials.
Average Trading Volume: 619,144
Technical Sentiment Signal: Sell
Current Market Cap: $11.97M
Learn more about PHIO stock on TipRanks’ Stock Analysis page.